Telazine (Trifluoperazine) is generally used to provide symptomatic relief across two primary therapeutic domains, managing pronounced symptoms that interfere with mental stability and daily function.

What Telazine Treats: Main Uses and Benefits

This medication is considered relevant in clinical settings marked by heightened patient distress, applicable within therapeutic domains that involve acute or disruptive symptom patterns. Its primary uses include the management of psychotic disorders, such as schizophrenia, and the short-term symptomatic support for severe, non-psychotic generalized anxiety.

Management of Psychotic Symptoms For patients with psychotic disorders, Telazine is applied to address challenging, heightening symptoms like delusions, hallucinations, and severe disorganized thinking. Using this medication supports patients in addressing these disruptive manifestations, which contributes to maintaining a sense of stability during recurrent episodes.

Stabilization of Severe Anxiety and Agitation In the context of severe anxiety, Telazine may assist in easing the burden of excessive worry, internal tension, and motor restlessness. This supportive therapeutic benefit helps patients cope more steadily with symptom fluctuations, particularly when symptoms become temporarily overwhelming.

---

Quick Fact: Relief for Disorganized Thought	Condition	Symptom Type	Patient Benefit
Psychotic Disorders	Delusions, Hallucinations	Supports symptom management
Severe Anxiety States	Agitation, Internal Tension	Contributes to easing symptom load

Regulatory References

1. NIH MedlinePlus Drug Information

Official Population Eligibility for Telazine (Trifluoperazine)

Regulatory agencies define the eligibility for Telazine by establishing clear allowances and absolute prohibitions across specific patient groups. Eligibility is granted for adults for the management of psychotic disorders, and for children aged 6 to 12 years in controlled settings for schizophrenia.

Category	Regulatory Status
Populations for whom use is allowed	Adults; Children aged 6–12 years (for psychotic disorders); Short-term treatment (up to 12 weeks) of generalized non-psychotic anxiety in adults.
Populations for whom use is not recommended	Elderly patients with dementia-related psychosis; Use during pregnancy or breastfeeding.
Populations for whom use is contraindicated	Hypersensitivity to trifluoperazine or other phenothiazines; Severe liver damage or blood dyscrasias; Comatose or greatly depressed CNS states; Congenital long QT syndrome.

Eligibility is further constrained by age and clinical condition. Use is not established for children under 6 years of age. Older adults with dementia-related psychosis are not approved for treatment due to an increased risk of death, as stated by regulatory warnings. Use requires caution in patients with cardiovascular disease, renal impairment, and conditions like Parkinson's disease or glaucoma. Neonates exposed during the third trimester of pregnancy are at risk of adverse symptoms, and use during lactation is generally not recommended.

The official regulatory profile for Telazine identifies specific combinations and conditions that result in clinically significant interactions, structured by their effect and regulatory status.

Contraindicated Combinations and Conditions

Co-administration with certain QT-prolonging drugs is strictly prohibited due to an officially documented risk of QTc interval prolongation. The use of Telazine is also contraindicated with Adrenaline (Epinephrine), as this combination can reverse Adrenaline’s pressor effect, potentially causing paradoxical hypotension. Furthermore, the use of this medication is prohibited in comatose states, in severe central nervous system (CNS) depression induced by other substances, and in patients with pre-existing hepatic disease.

Pharmacodynamic Effects and Exposure Modification

Combining Telazine with other CNS depressants (including alcohol and general anesthetics) may result in an additive CNS depressive effect. An antagonistic effect is noted with Levodopa, where Telazine may impair its antiparkinson effect. Substances that modify Telazine exposure are also documented: Antacids containing aluminum salts can reduce drug absorption, leading to a decreased serum concentration. Conversely, tobacco smoking is noted to potentially increase the clearance of phenothiazines, which may reduce Telazine’s efficacy.

Timing Requirements

An interaction-related restriction requires that Telazine must be discontinued 24 hours prior to administration of Metrizamide for certain diagnostic procedures.

Telazine (trifluoperazine) is a phenothiazine derivative that modulates central nervous system neurotransmission through multiple biological targets.

Its primary mechanistic action is non-selective antagonism at postsynaptic dopamine receptors, specifically the D2 subtype, within mesolimbic and mesocortical projection pathways. This dopaminergic blockade elevates cyclic adenosine monophosphate (cAMP) levels due to relief of the D2 receptor's inhibitory control over adenylate cyclase, altering intracellular signaling.

Secondary interactions include antagonism at alpha-1A adrenergic receptors and antagonism at the neuron-specific vesicular protein, calcyon. Furthermore, Telazine functions as an inhibitor of various Calmodulin proteins ( Calmodulin-1, -2, -3), an effect which disrupts intracellular Ca^2+ signaling cascades. The cumulative effect of these D2 receptor and Calmodulin interactions results in broad modulation of neuronal activity, affecting basal metabolism, central thermoregulation, and vasomotor tone.

Telazine is administered via the oral route as a tablet or liquid concentrate, and via intramuscular (IM) injection for acute clinical scenarios. Administration is based on two primary, indication-specific dosing regimens. For the symptomatic management of psychotic disorders, the typical adult oral dose begins at 2 mg to 5 mg twice daily and is gradually titrated to a maintenance level, usually between 15 mg and 20 mg daily, with a maximum of 40 mg daily. Conversely, the use of Telazine for severe non-psychotic anxiety is structured with a lower maximum limit of 6 mg daily and is restricted to a duration not exceeding 12 weeks.

Regardless of the form, the medicine can be taken with or without food. Doses for older adults are typically initiated at half the standard adult dose and increased more gradually, reflecting a required population-specific adjustment. Furthermore, to ensure proper absorption, the medicine should not be taken within two hours of an antacid. Once treatment is established, the goal is to maintain the patient on the lowest required dose; when treatment is to be stopped, a gradual withdrawal is recommended to avoid procedural issues. This framework defines the standardized administration protocol for the medication.

Telazine: Recent Clinical Evidence

Evidence for Use in Psychotic Disorders

The core evidence for Telazine (Trifluoperazine) comes from research exploring its use in conditions associated with acute or disruptive episodes, such as schizophrenia. Research has examined how symptoms change over time in adult populations with these conditions. The studies typically observed groups receiving Telazine compared to a placebo or to groups where other First-Generation Antipsychotics (FGAs) were evaluated.

The studies monitored outcomes reflecting overall stabilization, known to researchers as Global Clinical State, and also tracked specific psychotic symptoms, where outcomes related to episodic or acute changes were measured. Research also monitored outcomes related to systemic or functional imbalance, such as relapse and hospitalization rates, in both acute and maintenance treatment settings. Findings describe patterns observed in the studies over both short-term periods (weeks) and medium-term intervals (up to a few months).

The evidence quality that varies across studies is noted, with regulatory bodies often describing the overall certainty of findings as Moderate when Telazine was evaluated against an inactive placebo. However, the quality of research comparing Telazine directly to many currently available medicines is often described as Low to Very Low.

Evidence for Short-Term Use in Severe Anxiety

Research has explored Telazine for the short-term use in managing non-psychotic generalized anxiety. This application was evaluated in adult outpatients experiencing conditions where symptoms may vary in intensity, such as intense worry and motor restlessness. The evidence derived from these settings provides insight into short-term changes in generalized anxiety symptoms.

Findings describe group patterns, not personal outcomes; and its use was studied in research contexts involving fluctuating or unstable symptoms. However, the follow-up durations were limited, and data for this particular use remain insufficient.

Evidence Quality and Research Uncertainty

The overall research landscape for Telazine is characterized by evidence quality that varies across studies and design. Many of the foundational studies are older, meaning they were conducted before current reporting and methodological standards were put in place. Evidence is limited in areas such as direct, contemporary comparisons between Telazine and newer prescription medicines. Research shows limited data on how outcomes might differ in older adults or in populations with specific comorbid medical conditions. Further study is ongoing or needed to fully address the uncertainties, especially concerning long-term outcomes.

Key Studies & References

1. TRIFLUOPERAZINE tablet, film coated - NIH DailyMed (FDA Approved Labeling)
2. Trifluoperazine: MedlinePlus Drug Information (NIH)

Common questions about Telazine (FAQ)

---

Q: How quickly does Telazine start to work for its main purpose?

According to official product information, the medicine’s peak effect is typically observed in the body within two to four hours after a dose is administered. Information in the product label notes the typical peak effect timing, but the timeline for observing overall stabilization is variable and depends on the prescribed treatment plan.

---

Q: What is the typical expectation for Telazine's effects to wear off?

The therapeutic action of the medicine is generally understood to last for an average duration of four to six hours after administration. This expected duration is a factor in how the medicine is structured in official guidelines.

---

Q: Does Telazine interact with blood pressure medication?

Regulatory documents state a specific prohibition regarding co-administration with Adrenaline (Epinephrine), as this combination may lead to a dangerous drop in blood pressure (paradoxical hypotension). Core official information does not consistently define specific interactions with general classes of anti-hypertensive drugs beyond the contraindication with Epinephrine.

---

Q: Can Telazine affect one's ability to drive or operate machinery?

Official safety documents list common side effects such as dizziness, drowsiness, and blurred vision. Regulatory warnings indicate that because these common side effects can impair mental alertness, caution is necessary when performing complex or high-risk tasks, such as driving or operating heavy machinery.

---

Q: Is it normal to feel a bit restless after taking Telazine?

Official documents classify Extrapyramidal Symptoms (EPS), which can include a feeling of restlessness (Akathisia), as a common adverse reaction. This is particularly noted when treatment is first started or after a dose is changed.

---

Q: Where can I find the official regulatory information for Telazine?

Authoritative information for Telazine is published and maintained by government drug authorities worldwide, such as the FDA in the United States, the EMA in Europe, and Health Canada. Patient-focused, descriptive summaries that use official source data are also often provided by government health institutions.

---

Q: How does the effectiveness of Telazine change over time?

Regulatory-cited research provides evidence for its use in both short-term (weeks) and medium-term intervals (up to a few months). For psychotic disorders, clinical information addresses its role in maintenance treatment, although research on efficacy over very long, multi-year periods is often noted in official sources as limited.

---

Q: Does Telazine affect sleep patterns?

Official safety profiles document potential effects on sleep. Drowsiness is commonly reported, and some users may also experience insomnia, or difficulty falling or staying asleep.

---

Q: Is it common to have headaches when starting Telazine?

Headache is listed in some comprehensive regulatory safety profiles as a documented side effect of the medicine.

---

Q: Does Telazine show up on standard drug tests?

The active ingredient, Trifluoperazine, is included in specialized testing panels used by clinical laboratories to detect the presence of antipsychotic drugs. Detection is typically performed using advanced analytical methods, such as mass spectrometry.

---

Q: Does Telazine cause weight changes?

Changes in weight are documented in comprehensive safety profiles as a potential adverse reaction. Specifically, official sources include weight gain as a possibility.

---

Q: Is Telazine available as a generic drug?

The active component, Trifluoperazine, is available in the market as a generic oral tablet formulation.

---

Q: Are there different strengths of Telazine available?

The oral tablet formulation of the medicine is available in multiple strengths to allow for the individualized dosing prescribed by healthcare providers. Official labeling commonly lists strengths such as 1 mg, 2 mg, 5 mg, and 10 mg tablets.

---

Q: Does Telazine affect blood sugar levels?

Official warnings and studies indicate that this medication may affect glucose metabolism and potentially increase blood sugar levels. Due to this risk, specific monitoring may be recommended for individuals with diabetes.

---

Q: Is it important to take Telazine at the same time every day?

Regulatory documents indicate that because the drug has a long duration of action, it may be administered once or twice daily. This dosing frequency is based on the drug's duration of action.

---

Q: Can Telazine cause digestive upset like nausea or diarrhea?

While the list of common side effects focuses on dry mouth and constipation, comprehensive regulatory safety profiles also document side effects that may include digestive upset such as nausea and vomiting.

---

Q: Does Telazine require any special monitoring while being used?

Official regulatory documents indicate that monitoring may be recommended during treatment. Patients at risk for metabolic complications should have their weight or BMI monitored. For individuals with a history of low white blood cell count (WBC), official documentation notes that monitoring of the Complete Blood Count (CBC) may be recommended.

---

Q: Can using Telazine affect one's appetite?

Changes in appetite are documented in comprehensive safety profiles. These documented effects include both loss of appetite (anorexia) and, in some cases, increased appetite.

---

Q: Is Telazine considered a first-line or later-line treatment?

For psychotic disorders, conventional antipsychotics (like Telazine) are often described in clinical guidelines as a later-line treatment option, sometimes used as an alternative to newer agents. For its short-term use in non-psychotic anxiety, the official indication is restrictive and describes its use as an alternative to other less toxic agents.

How to Store and Dispose of Telazine (Trifluoperazine)

Telazine tablets must be stored at Controlled Room Temperature (CRT), maintained between 20 C and 25 C (68 F and 77 F), with permitted excursions up to 30 C. The medication must be kept in its original container, which must be tightly closed, and protected from both moisture and excessive heat.

---

Child Safety and Disposal

For safety, Telazine must be stored out of the reach and sight of children, and safety caps must be locked after each use. Unused or expired medication should be disposed of using an official drug take-back program. If a program is unavailable, follow the labeled instruction to mix the tablets with an unappealing substance (like dirt or coffee grounds) and place the mixture into a sealed bag before discarding it in the household trash. Do not crush the tablets.